Drug Guide
Acetohexamide
Classification
Therapeutic: Antidiabetic agent
Pharmacological: Sulfonylurea
FDA Approved Indications
- Management of type 2 diabetes mellitus as an adjunct to diet and exercise
Mechanism of Action
Stimulates insulin release from pancreatic beta cells by inhibiting ATP-sensitive potassium channels, leading to insulin secretion and decreased blood glucose levels.
Dosage and Administration
Adult: Initial dose: 250 mg once daily, titrate based on blood glucose response. Typical maintenance dose: 250-500 mg daily in divided doses.
Pediatric: Not typically used in pediatric patients.
Geriatric: Start at lower doses due to potential sensitivity and comorbidities; monitor glycemic response closely.
Renal Impairment: Use with caution; dose adjustments may be necessary. Frequent monitoring is advised.
Hepatic Impairment: Use with caution; dose adjustments may be necessary; monitor hepatic function.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed in body tissues.
Metabolism: Metabolized in the liver.
Excretion: Excreted primarily via the kidneys.
Half Life: Approximately 4 hours.
Contraindications
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Hypersensitivity to sulfonylureas
Precautions
- History of hypersensitivity reactions, liver disease, renal impairment, or pregnancy. Women who are pregnant or breastfeeding should consult healthcare providers before use.
Adverse Reactions - Common
- Hypoglycemia (Common)
- Gastrointestinal disturbances (nausea, vomiting, epigastric discomfort) (Common)
Adverse Reactions - Serious
- Allergic skin reactions (rash, urticaria) (Rare)
- Blood dyscrasias (aplastic anemia, leukopenia) (Rare)
Drug-Drug Interactions
- Other antidiabetic agents (risk of hypoglycemia), NSAIDs (may enhance hypoglycemic effect), alcohol (may potentiate hypoglycemia)
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor blood glucose levels regularly, assess for signs of hypoglycemia, liver function, and renal function.
Diagnoses:
- Risk for hypoglycemia
- Ineffective tissue perfusion related to hypoglycemia
Implementation: Administer with meals to reduce gastrointestinal upset; educate patient on recognizing hypoglycemia.
Evaluation: Evaluate glycemic control and monitor side effects.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Monitor blood glucose regularly.
- Recognize symptoms of hypoglycemia and how to treat it (e.g., glucose tablets).
- Report signs of allergic reactions or unusual symptoms to healthcare provider.
Special Considerations
Black Box Warnings:
- Risk of hypoglycemia, especially in improper dosing or with other hypoglycemic agents.
Genetic Factors: No specific genetic considerations known.
Lab Test Interference: May interfere with certain blood glucose test readings.
Overdose Management
Signs/Symptoms: Severe hypoglycemia including sweating, weakness, confusion, seizures, coma.
Treatment: Administer glucose orally if conscious; if unconscious, administer dextrose intravenously; monitor blood glucose levels closely.
Storage and Handling
Storage: Store at room temperature, 20°C to 25°C (68°F to 77°F). Keep container tightly closed.
Stability: Stable under recommended storage conditions.